We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.